18.04.2012 - UCBs Cimzia has succeeded in a phase III. That raises hope that the TNF-α inhibitor could gain additional sales in the highly competitive anti-inflammation market.
Brussels – The TNF alpha inhibitor has met the primary endpoint in a phase III trial to treat adult onset of active axial spondoyloarthritis (AXSA). The study enrolled 325 patients with AXSA who were assigned to treatment with one of two doses of Cimzia (certolizumab pegol) or placebo over a 24-week period. The trial has shown a 20 per cent improvement in the Assessment of Spondyloarthritis International Society (ASAS20) response at week 12 compared to placebo. UCB expects to file for approval in this indication later this year. The pegylated humanised antibody fragment Cimzia (certolizumab pegol) is already approved in Europe and the US for rheumatoid arthritis and in the US for Crohn's disease, although the EU rejected UCB's application to market the drug in the latter indication in 2008. It is UCB's second-biggest product with sales of €312m last year, up more than 50 per cent compared to 2010. Axial spondyloarthritis is a collective name for a series of inflammatory rheumatic diseases of the spine, joints, ligaments and tendons, and includes a spinal condition known as ankylosing spondylitis. Expanding the labelling for Cimzia in this indication is important for UCB to make headway against the drug's rivals in the competitive anti-TNF alpha sectorlike Enbrel (Amgen, Pfizer and others), Humira (Abbott, Eisai ) and Johnson & Johnson's Remicade. The competitors fear the appearance of biosimilar rivals entering the market after the drug's patent expiry in 2014. In addition to the axial spondyloarthritis indications, UCB is also planning to submit Cimzia for psoriatic arthritis by the end of the year, and is also awaiting approval of the drug for rheumatoid arthritis in Japan, where it has been co-developed by Astellas Pharma.
26.08.2016 Adocia said it would discontinue its diabetic foot ulcer programme after its lead product BioChaperone PDGF disappointed in Phase III. The French company will turn the focus on its earlier-stage products.
24.08.2016 Pharma major Pfizer is putting the cherry on top of its multi-billion-dollar takeover of Medivation with the acquisition of AstraZeneca’s antibiotics for a cool US$1.5bn. With the divestment, AZ aims to further sharpen its focus.
23.08.2016 Cambridge University-allied investor Cambridge Innovation Capital has raised £75m (€87m) to reinvest in technology and healthcare companies. Among the backers were Woodford Investment and Winton Ventures.
19.08.2016 Together with partner Johnson & Johnson, Danish biotech Genmab is now one step closer to FDA approval with its combination treatment for multiple myeloma after its submission of a supplemental Biologics License Application. In July, Genmab was granted a Breakthrough Therapy Designation (BTD) for its blood cancer therapy.
17.08.2016 Philip Hammond, the UK’S chancellor has announced the government will guarantee funding for EU-backed "structural and investment fund" projects whose timelines extend beyond the UK’s departure from the EU, provided the projects are signed prior to this year's Autumn Statement on the UK budget. The decision ensures continued funding for farmers, companies and institutions involved in the EU’s Horizon 2020 project. The move could cost the UK government up to £6bn (€6.9bn).
15.08.2016 Back in April, the American FDA gave the green light for the colorectal cancer-screening test Epi procolon. Now Berlin-based diagnostics specialist Epigenomics is considering a secondary listing in the US. A draft of the required registration document was confidentially submitted to the US Securities and Exchange Commission (SEC).
09.08.2016 Hungarian Gedeon Richter and Irish Allergan are staying on course in the face of dissappointing Phase III results for depression drug cariprazine. The partners will now begin another Phase III study needed for approval.
08.08.2016 Araclon Biotech’s Alzheimer’s vaccine ABvac40 is going forward into Phase II after showing a good safety profile in Phase I. The promising trial results were presented at the Alzheimer’s Association International Conference.
FILTRODISC™ BIO SD is a filtration system which removes particles (e.g. cells, bacteria, yeast), impurities (e.g. HCP, DNA) and other turbid matter from process liquids (e.g. fermentation broths). more